Polycystic ovary syndrome: epidemiologic assessment of prevalence of systemic rheumatic and autoimmune diseases.
Androgen
Autoimmune disease
Polycystic ovary syndrome
Rheumatic disease
Rheumatoid arthritis
Systemic sclerosis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
30
05
2021
accepted:
27
06
2021
revised:
20
06
2021
pubmed:
4
7
2021
medline:
20
11
2021
entrez:
3
7
2021
Statut:
ppublish
Résumé
Polycystic ovary syndrome (PCOS) causes anovulation and hyperandrogenism. Hormonal imbalance is known to contribute to systemic autoimmune diseases. To examine the frequency of certain rheumatic diseases in PCOS. This retrospective study utilized and analyzed electronic medical records from January 2004 through February 2020. A diagnosis of PCOS and specified rheumatic diseases was searched using ICD-9 and ICD-10 codes. A total of 754 adult patients with PCOS and 1,508 age- and body mass index-matched patients without PCOS were included. Frequencies of the rheumatic diseases were compared between PCOS and non-PCOS subjects or literature data. The prevalence of rheumatoid arthritis (RA) was found to be 2.25% (17/737) in the PCOS patients, numerically higher than 1.26% (19/1489) in the non-PCOS subjects. The difference was significant with a confidence level of 90% (1.04-3.15) but not at 95% with an odds ratio of 1.808 (95% CI = 0.934-3.4, p = 0.0747). When compared with the literature data from the US female population, the prevalence of RA in PCOS patients was significantly higher (2.25% vs. 1.40%, p < 0.0001). Among the autoimmune diseases examined, both systemic sclerosis (0.40% vs. 0.0%, p = 0.0369) and undifferentiated connective tissue disease (0.53% vs. 0.0%, p = 0.0123) were significantly more frequent in the PCOS patients than the non-PCOS. Additionally, PCOS patients had a significantly higher frequency of osteoarthritis than non-PCOS patients (5.44% vs. 2.92%, p = 0.0030) with an odds ratio of 1.913 (95% CI = 1.239-2.955). We have shown unprecedentedly that certain rheumatic diseases are more prevalent in PCOS. This study provides important insight into autoimmunity in association with PCOS. Key Points • Polycystic ovary syndrome is postulated to cause systemic autoimmune disease due to its hormonal imbalance. • We conducted the first epidemiologic assessment of the prevalence of systemic autoimmune diseases. • Certain autoimmune and rheumatic diseases are more prevalent in polycystic ovary syndrome.
Sections du résumé
BACKGROUND
BACKGROUND
Polycystic ovary syndrome (PCOS) causes anovulation and hyperandrogenism. Hormonal imbalance is known to contribute to systemic autoimmune diseases.
OBJECTIVE
OBJECTIVE
To examine the frequency of certain rheumatic diseases in PCOS.
METHODS
METHODS
This retrospective study utilized and analyzed electronic medical records from January 2004 through February 2020. A diagnosis of PCOS and specified rheumatic diseases was searched using ICD-9 and ICD-10 codes. A total of 754 adult patients with PCOS and 1,508 age- and body mass index-matched patients without PCOS were included. Frequencies of the rheumatic diseases were compared between PCOS and non-PCOS subjects or literature data.
RESULTS
RESULTS
The prevalence of rheumatoid arthritis (RA) was found to be 2.25% (17/737) in the PCOS patients, numerically higher than 1.26% (19/1489) in the non-PCOS subjects. The difference was significant with a confidence level of 90% (1.04-3.15) but not at 95% with an odds ratio of 1.808 (95% CI = 0.934-3.4, p = 0.0747). When compared with the literature data from the US female population, the prevalence of RA in PCOS patients was significantly higher (2.25% vs. 1.40%, p < 0.0001). Among the autoimmune diseases examined, both systemic sclerosis (0.40% vs. 0.0%, p = 0.0369) and undifferentiated connective tissue disease (0.53% vs. 0.0%, p = 0.0123) were significantly more frequent in the PCOS patients than the non-PCOS. Additionally, PCOS patients had a significantly higher frequency of osteoarthritis than non-PCOS patients (5.44% vs. 2.92%, p = 0.0030) with an odds ratio of 1.913 (95% CI = 1.239-2.955).
CONCLUSION
CONCLUSIONS
We have shown unprecedentedly that certain rheumatic diseases are more prevalent in PCOS. This study provides important insight into autoimmunity in association with PCOS. Key Points • Polycystic ovary syndrome is postulated to cause systemic autoimmune disease due to its hormonal imbalance. • We conducted the first epidemiologic assessment of the prevalence of systemic autoimmune diseases. • Certain autoimmune and rheumatic diseases are more prevalent in polycystic ovary syndrome.
Identifiants
pubmed: 34216315
doi: 10.1007/s10067-021-05850-0
pii: 10.1007/s10067-021-05850-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4837-4843Informations de copyright
© 2021. International League of Associations for Rheumatology (ILAR).
Références
Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333(13):853–861
doi: 10.1056/NEJM199509283331307
Prevention CfDCa. PCOS (polycystic ovary syndrome) and diabetes. March 24, 2020. https://www.cdc.gov/diabetes/basics/pcos.html
Rotterdam EA-SPCWG (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25
Azziz R, Carmina E, Dewailly D et al (2006) Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91(11):4237–4245
doi: 10.1210/jc.2006-0178
Wekker V, van Dammen L, Koning A et al (2020) Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update 26(6):942–960
doi: 10.1093/humupd/dmaa029
Azziz R, Marin C, Hoq L, Badamgarav E, Song P (2005) Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 90(8):4650–4658
doi: 10.1210/jc.2005-0628
Glueck CJ, Goldenberg N (2019) Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism 92:108–120
doi: 10.1016/j.metabol.2018.11.002
Angstwurm MW, Gartner R, Ziegler-Heitbrock HW (1997) Cyclic plasma IL-6 levels during normal menstrual cycle. Cytokine 9(5):370–374
doi: 10.1006/cyto.1996.0178
Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83(8):2907–2910
pubmed: 9709967
Cutolo M, Capellino S, Sulli A et al (2006) Estrogens and autoimmune diseases. Ann N Y Acad Sci 1089:538–547
doi: 10.1196/annals.1386.043
Romitti M, Fabris VC, Ziegelmann PK, Maia AL, Spritzer PM (2018) Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis. Endocr Connect 7(11):1158–1167
doi: 10.1530/EC-18-0309
Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17(5):615–620
pubmed: 10544849
Gabriel SE, Crowson CS, O’Fallon WM (1999) The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum 42(3):415–420
doi: 10.1002/1529-0131(199904)42:3<415::AID-ANR4>3.0.CO;2-Z
Martin M. Crane BS, Julie Priest, Nasha Wang, Henry Krzywy, Ganguly R (2013) Population-based analysis of treatment patterns for recently diagnosed rheumatoid arthritis patients in the United States. Arthritis & Rheumatism 65(NUMBER 10 (SUPPLEMENT)):S448
Arduc A, Aycicek Dogan B, Bilmez S et al (2015) High prevalence of Hashimoto’s thyroiditis in patients with polycystic ovary syndrome: does the imbalance between estradiol and progesterone play a role? Endocr Res 40(4):204–210
doi: 10.3109/07435800.2015.1015730
Petrikova J, Lazurova I, Yehuda S (2010) Polycystic ovary syndrome and autoimmunity. Eur J Intern Med 21(5):369–371
doi: 10.1016/j.ejim.2010.06.008
Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, Saag KG (2003) Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum 33(2):72–82
doi: 10.1016/S0049-0172(03)00084-2
Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48(8):2246–2255
doi: 10.1002/art.11073
Straub RH (2007) The complex role of estrogens in inflammation. Endocr Rev 28(5):521–574
doi: 10.1210/er.2007-0001
Pfeilschifter J, Koditz R, Pfohl M, Schatz H (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23(1):90–119
doi: 10.1210/edrv.23.1.0456
Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33(6):981–1030
doi: 10.1210/er.2011-1034
Rosenfield RL, Ehrmann DA (2016) The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 37(5):467–520
doi: 10.1210/er.2015-1104
Annibalini G, Agostini D, Calcabrini C et al (2014) Effects of sex hormones on inflammatory response in male and female vascular endothelial cells. J Endocrinol Invest 37(9):861–869
doi: 10.1007/s40618-014-0118-1
Lobo RA, Carmina E (2000) The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132(12):989–993
doi: 10.7326/0003-4819-132-12-200006200-00010
Verthelyi D, Klinman DM (2000) Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 100(3):384–390
doi: 10.1046/j.1365-2567.2000.00047.x
Cutolo M, Balleari E, Giusti M, Intra E, Accardo S (1991) Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 34(1):1–5
doi: 10.1002/art.1780340102
Moulton VR (2018) Sex hormones in acquired immunity and autoimmune disease. Front Immunol 9:2279
doi: 10.3389/fimmu.2018.02279
Straub RH, Bijlsma JW, Masi A, Cutolo M (2013) Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases–the 10-year update. Semin Arthritis Rheum 43(3):392–404
doi: 10.1016/j.semarthrit.2013.04.008
Koller MD, Templ E, Riedl M et al (2004) Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum Dis 63(12):1677–1680
doi: 10.1136/ard.2003.018325
Chikanza IC, Petrou P, Kingsley G, Chrousos G, Panayi GS (1992) Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 35(11):1281–1288
doi: 10.1002/art.1780351107
Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110–2121
doi: 10.1056/NEJMra1100359
Alpizar-Rodriguez D, Pluchino N, Canny G, Gabay C, Finckh A (2017) The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology (Oxford) 56(8):1254–1263
Campochiaro C, Host LV, Ong VH, Denton CP (2018) Development of systemic sclerosis in transgender females: a case series and review of the literature. Clin Exp Rheumatol. 36(4):50–52
pubmed: 29465362
Mosca M, Tani C, Talarico R, Bombardieri S (2011) Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases. Autoimmun Rev 10(5):256–258
doi: 10.1016/j.autrev.2010.09.013
Valentini G, Pope JE (2020) Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma? Autoimmun Rev. 19(11):102659
doi: 10.1016/j.autrev.2020.102659
Gao L, Gu Y, Yin X (2016) High serum tumor necrosis factor-alpha levels in women with polycystic ovary syndrome: a meta-analysis. PLoS One. 11(10):e0164021
doi: 10.1371/journal.pone.0164021
Younis A, Hawkins K, Mahini H, Butler W, Garelnabi M (2014) Serum tumor necrosis factor-alpha, interleukin-6, monocyte chemotactic protein-1 and paraoxonase-1 profiles in women with endometriosis, PCOS, or unexplained infertility. J Assist Reprod Genet 31(11):1445–1451
doi: 10.1007/s10815-014-0237-9
Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361(9):888–898
doi: 10.1056/NEJMra0707449
Reyes C, Leyland KM, Peat G, Cooper C, Arden NK, Prieto-Alhambra D (2016) Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study. Arthritis Rheumatol 68(8):1869–1875
doi: 10.1002/art.39707
Abbasi J (2017) Can exercise prevent knee osteoarthritis? JAMA 318(22):2169–2171
doi: 10.1001/jama.2017.16144
Messier SP, Mihalko SL, Legault C et al (2013) Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 310(12):1263–1273
doi: 10.1001/jama.2013.277669
Legro RS (2012) Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 30(6):496–506
doi: 10.1055/s-0032-1328878
Kabakchieva P, Georgiev T, Gateva A, Hristova J, Kamenov Z (2021) Polycystic ovary syndrome and (pre)osteoarthritis: assessing the link between hyperandrogenism in young women and cartilage oligomeric matrix protein as a marker of cartilage breakdown. Clin Rheumatol. https://doi.org/10.1007/s10067-021-05753-0